An array of 15 HIV-1 recombinant protein and associated peptides matched very closely to ELISA results in evaluating the intricacies of associated antibody binding patterns.
The new cartridge-based test runs on the firm's GeneXpert platform and provides a 90-minute molecular diagnosis of HIV in high-risk individuals and infants.
The Phase II grant will provide the company with funding to develop a commercial-ready version of the test.
The HIV test is the first of several NGS-based infectious disease tests the company plans to develop, with a hepatitis C virus test following close behind.
Tests in development for the Alere q include HIV, tuberculosis, and Ebola assays, and it will initially be targeted to low-resource settings in the developing world.
The assay is intended for early infant diagnosis of HIV infection.
The fully automated self-confirming assay will simultaneously detect HIV/AIDS antibodies and viral RNA in a single specimen.
University Hospitals' Deepgen HIV assay will use Advanced Biological Laboratories' DeepChek software to help monitor drug resistance and minority variants in HIV strains.
The real-time PCR assay is designed to detect and identify HIV, hepatitis B virus, and hepatitis C virus in donations of human whole blood and blood components.
Shipping of the assay, Cepheid's eighth product release in 2014, is anticipated to begin in February 2015.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.